Almirall, S.A.
7 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
8
Ending by 2030
Feb 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 28, 2026The maintenance fee for Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities (US 10,300,072) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
- 1 fee due Jul 12, 2027The maintenance fee for Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities (US 9,233,108) comes due Jul 12, 2027. Unpaid by Jan 12, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,875,630 | Novel Process Salts Compositions and Use In force · High confidence | In force | High confidence | |
| US 7,964,615 | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptor In force · From the USPTO record | In force | From the USPTO record | |
| US 8,044,205 | Process for manufacturing 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide In force · From the USPTO record | In force | From the USPTO record | |
| US 8,258,308 | Amino nicotinic and isonicotinic acid derivatives as DHODH inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 10,085,974 | Novel Dosage and Formulation In force · Medium confidence | In force | Medium confidence | |
| US 11,000,517 | Novel Dosage and Formulation In force · Medium confidence | In force | Medium confidence | |
| US 8,865,728 | Combinations comprising methotrexate and DHODH inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 8,598,363 | Process for Manufacturing 2-[(3,5-Difluoro-3'-Methoxy-1,1'-Biphenyl-4 Yl)amino]nicotinic Acid In force · High confidence | In force | High confidence | |
| US 9,737,520 | Aclidinium for use in improving the quality of sleep in respiratory patients In force · From the USPTO record | In force | From the USPTO record | |
| US 9,233,108 | Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 12: 7 patents in force now held by others · 47 lapsed for an unpaid fee · 26 ended at full term · 3 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 7 abandoned · 25 no status recorded